Arena Pharmaceuticals To Release Briefing Documents On September 14 Over Lorcaserin

Loading...
Loading...
Arena Pharmaceuticals, Inc.
ARNA
has had its price target lowered to $5 (from $6) by Jefferies & Company, whic believes that the Lorcaserin heart valve safety analysis didn't meet the FDA cutoff, given the history of this class of weight loss drugs. Arena Pharmaceuticals will release safety data documents on September 14, which will be re-evaluated as Jefferies remains on the sidelines after witnessing a 100% stock appreciation from the company. Arena Pharmaceuticals, Inc. closed yesterday at $7.17 and is maintained as "hold".
Market News and Data brought to you by Benzinga APIs
Posted In: Analyst ColorNewsPrice TargetFDAMarketsAnalyst RatingsArena PharmaceuticalsBiotechnologyHealth CareJefferies & Company
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...